Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
about
Regulation of Natural Killer Cell Function by STAT3Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerTrends and advances in tumor immunology and lung cancer immunotherapyDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Immunotherapeutic strategies in autoimmune uveitisBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Targeting the tumor microenvironment to enhance antitumor immune responsesImmunology and Immunotherapy of Head and Neck CancerChanging the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.Programmed death-ligand 1 expression in rectal cancer.The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.Targeted therapies in breast cancer: New challenges to fight against resistance.Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.Immunotherapy for Lung Cancer: Has it Finally Arrived?The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.Immune checkpoint dysfunction in large and medium vessel vasculitis.Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabThe immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.Identification of Shared Molecular Signatures Indicate the Susceptibility of Endometriosis to Multiple Sclerosis.Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
P2860
Q26752551-13BE0026-4CA3-4EF0-8847-1B33F01017FBQ26798047-A41FB008-9C22-47B0-9462-D5E3024129FFQ28067674-C47F7BFA-BACE-46EA-B9A2-BDAFB6C2291AQ30364312-58685449-F9AD-414B-88F6-B78D5DF244CDQ34274950-D9F26C04-6940-4E17-8949-28DFC36951B7Q34380489-F7FDFA39-F3F6-453A-BBF6-4431865ED8C4Q35176307-7A16D1DA-7EE0-49D0-8803-5CB6ED73B057Q36100837-3083C544-A48B-479B-A5F6-6E799EB68538Q36849676-138B8629-95B2-4417-9391-ED96F809A1BEQ37224577-AAE614D4-A8F5-49F1-8CCB-53C36FA987B1Q37486606-1248E311-B1E7-44D0-BC0A-A7D1BAB82466Q37515182-34AC6FF4-84C3-4565-AABD-4B144861137CQ37531844-D090C74A-769A-4A3E-8250-447FDDF25A28Q37716640-11A26B86-C390-48FE-82C8-36D01F7AA1BDQ37736868-6FFD3D4D-6768-479D-8895-4ED8A764157FQ37743048-7969DEF3-DF5B-4738-8A1E-0D12D79FBE12Q38210811-D06ACB2A-6180-4989-8179-DCA23A3AA781Q38222469-4F911186-5613-4B22-B4FC-1A9308CBD753Q38265555-0BB43D99-16F3-4D51-BC57-A78A9555CC5FQ38285859-1DD12018-D48E-47DF-8A41-9ABC0236CF0BQ38548889-9409622F-5544-40B0-A65F-AAB1E31A5040Q38720431-10D86729-09B2-4968-B2C3-2B3DC78AFC9AQ38897019-168F42E7-B958-4B07-9C7B-C8C9891D67E8Q39532047-2524C230-39ED-44D9-BD49-7BB01C7BDA58Q41048538-D6B9F547-F80D-4A41-A5FE-01E7D8154B58Q41708947-0661DBE5-A7E7-4A24-9406-730BD371E7B8Q45998119-EAAB68E8-3FFA-4840-8F2C-CB2C4AC63456Q48307020-04A315C6-AD81-4445-BA42-C7D4FB22CF20Q48375822-D95F0FD5-CEAB-4890-8217-051B9DBB4E28Q50351898-0921450F-F5B1-48D5-BC74-64C14BCECE4DQ53158997-95EBD75C-08E5-4086-A871-1D64278ED644Q58764307-7C9EA908-AA84-4EB7-A6E5-908230436886
P2860
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
@en
type
label
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
@en
prefLabel
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
@en
P2860
P356
P1476
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
@en
P2093
Alan G Ramsay
P2860
P304
P356
10.1111/BJH.12380
P407
P577
2013-05-21T00:00:00Z